Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.41% and Operating profit at 27.63% over the last 5 years
2
Negative results in Mar 25
3
With ROE of 13.08%, it has a attractive valuation with a 2.99 Price to Book Value
4
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,709 Million (Mid Cap)
23.00
NA
0.00%
-0.56
13.08%
2.99
Revenue and Profits:
Net Sales:
793 Million
(Quarterly Results - Jun 2025)
Net Profit:
138 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.94%
0%
4.94%
6 Months
30.92%
0%
30.92%
1 Year
53.97%
0%
53.97%
2 Years
41.14%
0%
41.14%
3 Years
48.23%
0%
48.23%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Beijing Winsunny Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.41%
EBIT Growth (5y)
27.63%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.95
Tax Ratio
8.77%
Dividend Payout Ratio
48.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.39%
ROE (avg)
17.86%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.99
EV to EBIT
18.47
EV to EBITDA
14.82
EV to Capital Employed
5.53
EV to Sales
2.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
29.94%
ROE (Latest)
13.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
792.80
844.10
-6.08%
Operating Profit (PBDIT) excl Other Income
182.50
177.20
2.99%
Interest
0.40
1.00
-60.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
137.70
158.90
-13.34%
Operating Profit Margin (Excl OI)
190.40%
177.70%
1.27%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -6.08% vs 5.33% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -13.34% vs 15.90% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,411.70
3,304.10
3.26%
Operating Profit (PBDIT) excl Other Income
575.20
586.10
-1.86%
Interest
3.60
5.50
-34.55%
Exceptional Items
1.50
1.00
50.00%
Consolidate Net Profit
492.10
492.30
-0.04%
Operating Profit Margin (Excl OI)
137.20%
145.70%
-0.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.26% vs 3.14% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -0.04% vs 11.99% in Dec 2023
About Beijing Winsunny Pharmaceutical Co., Ltd. 
Beijing Winsunny Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






